Breaking News, Collaborations & Alliances

Synairgen Partners with Ashfield Engage to Support the Commercialization of SNG001

Aims to bring innovative potential treatment to COVID-19 patients.

Author Image

By: Charlie Sternberg

Associate Editor

Synairgen plc, the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, has entered a partnership with global experts in strategic engagement and commercialization, Ashfield Engage.   Leveraging its COVID-19 experience, Ashfield Engage is supporting Synairgen as it builds its commercialization infrastructure for the needs of SNG001, in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters